[{"orgOrder":0,"company":"Marvel Biosciences","sponsor":"iBraiN Institute","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"Istradefylline","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Marvel Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Marvel Biosciences \/ iBraiN Institute","highestDevelopmentStatusID":"14","companyTruncated":"Marvel Biosciences \/ iBraiN Institute"}]

Find Clinical Drug Pipeline Developments & Deals by Marvel Biosciences

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : The collaboration aims to advance clinical development of the company's early-stage product MB204 (istradefylline) for the treatment of Rett syndrome.

                          Brand Name : MB-204

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          July 26, 2024

                          Lead Product(s) : Istradefylline

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Preclinical

                          Sponsor : iBraiN Institute

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank